|
Patent landscape, scope, and claims: |
US Patent 8,883,770 Scope and Claims: What the DCA Composition Patent Covers, Who Owns It, and Where It Sits in the US Landscape
US Patent 8,883,770 protects a US-specific composition claim tied to deoxycholic acid (DCA) with a defined “synthetic side chain” structural element, formulated with a pharmaceutically acceptable excipient. The claim set is framed as a composition of matter on the US patent register, not a method-of-use patent, and it is written to cover any composition meeting the DCA side-chain feature plus excipient selection.
What is US Patent 8,883,770 claiming for deoxycholic acid compositions?
Core claim premise (independent claim 1):
“A composition comprising deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof, wherein the DCA comprises a synthetic side chain of formula …, and a pharmaceutically acceptable excipient.”
Claim scope in plain technical terms
- Active component covered: DCA itself and pharmaceutically acceptable salts of DCA.
- Structural limitation: the DCA must incorporate a synthetic side chain defined by a chemical formula (the formula is the key limiting element).
- Formulation limitation: the DCA (with that synthetic side chain) is combined with a pharmaceutically acceptable excipient.
- What is not required by the independent claim (based on the claim wording provided):
- No specific route of administration (oral, topical, parenteral) is required in claim 1 as you supplied it.
- No dosage strength, concentration range, or particle size is required in the snippet provided.
- No specific excipient category is required other than “pharmaceutically acceptable excipient.”
Practical reading of the structural hook
For a composition claim like this, infringement turns on whether an accused product contains:
- a DCA molecule, as modified to include the claimed synthetic side chain, and
- is formulated with an excipient that qualifies as pharmaceutically acceptable.
Any product whose DCA does not have the same claimed synthetic side chain formula should fall outside claim 1, even if it is “DCA-like” or uses an unrelated derivatization.
Which specific DCA synthetic side chain elements define infringement risk under US 8,883,770?
The structural element you provided is the sole gating feature beyond “DCA or salt.” That formula is the patent’s claim determinant. From a landscape perspective, this typically means:
- Product design around the formula is feasible if a competitor uses a different side-chain structure or a different derivatization site that does not satisfy the formula limitation.
- Equivalent-structure arguments are limited in many US composition scenarios because literal infringement requires structural match. Doctrine of equivalents may be argued, but the more precise the structural formula limitation, the less room there usually is for “close enough” variants.
Key infringement tests likely to arise
- Does the drug substance contain the exact side chain as defined?
If the active ingredient is not the same chemical structure, the composition claim usually does not read onto it.
- Is the marketed form a salt covered as “pharmaceutically acceptable”?
Many DCA salt forms are plausible, so salt choice may not be a clean design-around if the underlying DCA molecule still carries the patented synthetic side chain.
- Is the product simply DCA plus excipient, or does it use additional active ingredients?
Composition claims typically still read on combination products if the patented composition element is present, but the exact dependent claims would govern if they require single-active formulations or exclude other actives.
What is the claim scope for salts and excipients under US 8,883,770?
Salt coverage
Your claim language includes “deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof.” This usually expands coverage to:
- inorganic salts (less common for bile acids but possible)
- organic salts (common)
- internal selection of “pharmaceutically acceptable” salts
This is a broad inclusion. Unless a competitor uses a salt that is argued not to be “pharmaceutically acceptable,” the salt prong tends to be low-friction for infringement.
Excipient coverage
“Pharmaceutically acceptable excipient” is broad by construction and usually captures:
- carriers and diluents
- binders
- disintegrants
- lubricants
- stabilizers
- buffers
- coatings
Because claim 1 does not constrain excipient class, design-arounds by excipient swapping alone should not avoid infringement if the active chemical meets the formula requirement.
How broad is the coverage: composition of matter vs formulation vs method of use?
Based on claim 1 as stated, the patent is structured as a composition claim. It does not read as:
- a method-of-treatment patent, or
- a manufacturing method patent, or
- a kit claim (no kit limitation appears in your text)
That matters commercially because:
- The patent may block approval and launch of products containing the claimed DCA derivative, even if a competitor uses a different dosing regimen, as long as the composition is within the claim.
What patents typically surround this kind of DCA-side-chain composition claim in the US?
For bile-acid derivative programs, patent estates commonly cluster into four buckets:
- Chemical entity patents (core structure, prodrugs, derivatized side chains)
- Salt and polymorph patents (forms, crystallinity, hydrates)
- Formulation patents (oral, topical, injectable, controlled release)
- Use patents (method of treatment, patient selection, biomarkers)
Your claim 1 is in bucket (1) with formulation language included at least at the excipient level. That creates a common landscape pattern:
- Another patent may own the same DCA derivative but with alternative independent claims covering salts, polymorphs, or specific formulations.
- Another patent may protect a particular delivery system or dosage form if the product is commercialized in a specific regimen.
When does US Patent 8,883,770 lose exclusivity and what are the US timing gates for generic entry?
You did not provide filing date, priority date, maintenance status, or expiration data for US 8,883,770. Without those dates, it is not possible to compute:
- patent term expiration,
- PTA/adjusted expiration,
- maintenance-driven lapse risk,
- the earliest reasonable Paragraph IV window tied to Orange Book listings.
No reliable exclusivity timeline can be derived solely from claim text.
What is the Orange Book status of US Patent 8,883,770, and which drugs are tied to it?
You did not provide any associated NDA/ANDA/BLA number, Orange Book listing, or label linkage. Without that, it is not possible to map the patent to:
- a specific FDA application,
- listed drug product(s),
- dosage form and strength,
- expiration and exclusivity coding on the Orange Book.
What would a Paragraph IV challenge need to argue against US 8,883,770?
At the claim level you provided, typical Paragraph IV theories against this claim would target:
- Non-infringement via side-chain mismatch: the accused DCA lacks the claimed synthetic side chain formula.
- Non-infringement via salt dispute: the accused compound is a different derivative, or a salt not considered “pharmaceutically acceptable,” though this is harder to win if the chemical is common.
- Invalidity via chemical obviousness or enablement: attacking whether the synthetic side chain structure would have been obvious and enabled at the filing date.
- Indefiniteness: if the formula is claimed, competitors sometimes challenge the clarity of structural definition, but that turns on the specification and exact drafting.
How does claim 1 limit design-around opportunities for competitors?
The claim is broad in excipient selection but narrow in the chemical defining element. That structure typically yields:
- High barrier for “same molecule” products: if competitors use the same DCA derivative structure, they face direct infringement risk.
- Lower barrier for “different side chain” products: if competitors design a DCA derivative with a different side chain that does not fall within the formula, they can often avoid the claim, even if the formulation is otherwise similar.
What dependent claims typically matter next (and how they could narrow or broaden the estate)?
You only provided claim 1. Dependent claims commonly do one of two things:
- Narrow further by specifying excipient classes, dosage forms, delivery routes, or particle properties.
- Broaden by alternative embodiments (other side-chain variants, salts, polymorphs) depending on how the specification is drafted.
If you only litigate on claim 1, the side-chain formula is the central issue. If dependent claims add constraints, competitors might still avoid those narrower claims while still being caught by claim 1.
Patent litigation risk: what issues would likely be litigated for this claim structure?
For a chemical composition claim written with a defined structural formula:
- Claim construction would dominate for the synthetic side-chain element.
- Chemical identity and analytical evidence would be pivotal (LC-MS, NMR, mass balance, impurity profile consistent with the side chain).
- Infringement mapping would focus on the molecular structure of the API used in the accused product.
Commercial exposure: what product scenarios likely implicate US 8,883,770?
Claim 1 is implicated if a product markets or uses:
- a DCA derivative that contains the claimed synthetic side chain, and
- is formulated with standard pharmaceutically acceptable excipients.
The most exposed scenarios are:
- the exact same API presented in any conventional oral/topical/injectable formulation (unless dependent claims narrow to a specific route)
- salts of the same API
- combination products where the patented DCA derivative is one component, unless claims or specification impose an exclusion
Key Takeaways
- US 8,883,770 claim 1 is a composition claim covering DCA (or pharmaceutically acceptable salts) containing a specific synthetic side chain defined by a formula, formulated with pharmaceutically acceptable excipient.
- Scope is broad on excipient, structurally narrow on the synthetic side chain.
- Main infringement and validity pressure points would be the exact synthetic side chain identity and chemical enablement/obviousness in the record.
- Patent timing, Orange Book linkage, and exclusivity windows cannot be determined from the claim text alone.
FAQs
-
How do you design around a DCA-side-chain composition patent when excipient changes won’t help?
You must change the API structure such that the synthetic side chain no longer meets the claimed formula.
-
Do composition claims cover combination drugs that include other active ingredients?
Usually yes if the patented composition element is present, subject to any dependent claim limitations and claim construction.
-
Are salts a strong design-around for a DCA composition claim that already covers “pharmaceutically acceptable salts”?
Salt selection alone is often insufficient because the claim explicitly includes pharmaceutically acceptable salts of the claimed DCA derivative.
-
What evidence most often decides infringement for formula-limited chemical composition claims?
Chemical identity testing demonstrating the exact side chain structure in the API used in the accused product.
-
What is the typical litigation sequence for a defined-structure composition claim?
Claim construction first, then chemical identity and infringement mapping using analytical evidence, followed by invalidity arguments tied to the specification and prior art.
References
- Patent claim text provided in the prompt (US Patent 8,883,770, claim 1).
More… ↓
⤷ Start Trial
|
